SCHEMBL502844

SCHEMBL502844

CCN(CC1COC(C)(C)N1C(=O)OC(C)(C)C)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 1/20 0.41
BRD4 O60885 1/20 0.37
TAAR1 Q96RJ0 3/20 0.37
GHSR Q92847 1/20 0.36
GFER P55789 1/20 0.36
HSD11B2 P80365 1/20 0.36
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
TSHR P16473 1/20 0.35
ALDH1A1 P00352 1/20 0.35
OPRK1 P41145 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ABCB1 P08183 1/20 0.34
GPR119 Q8TDV5 3/20 0.34
TGFBR1 P36897 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL502843 1.00 SPHK1 (0.41) SPHK1BRD4TAAR1GHSRGFER
SCHEMBL2082127 1.00 SPHK1 (0.41) SPHK1BRD4TAAR1GHSRGFER
SCHEMBL2083759 0.92 SPHK1 (0.38) SPHK1BRD4GHSRHSD11B2KMT2A
SCHEMBL2083757 0.92 SPHK1 (0.38) SPHK1BRD4GHSRHSD11B2KMT2A
SCHEMBL2079201 0.90 SLC6A2 (0.40) SPHK1BRD4HSD11B2KDM4EPKM
SCHEMBL2079206 0.90 SLC6A2 (0.40) SPHK1BRD4HSD11B2KDM4EPKM
SCHEMBL2081892 0.87 SPHK1 (0.41) SPHK1BRD4HSD11B2KDM4EPKM
SCHEMBL2081890 0.87 SPHK1 (0.41) SPHK1BRD4HSD11B2KDM4EPKM
SCHEMBL16087553 0.85 TAAR1 (0.41) TAAR1GFERKMT2AMEN1TSHR
SCHEMBL2082667 0.84 SPHK1 (0.39) SPHK1BRD4TAAR1GHSRHSD11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9132136-B2 Pharmaceutical combination HOFFMANN-LA ROCHE INC. (US) 2015-09-15 US disclosed
EP-2121641-B1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS HOFFMANN LA ROCHE (CH) 2014-09-24 EP disclosed
US-20130345201-A1 PHARMACEUTICAL COMBINATION HOFFMANN-LA ROCHE INC. (US) 2013-12-26 US disclosed
EP-2600853-A1 COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2013-06-12 EP disclosed
WO-2012016879-A1 COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-02-09 WO disclosed
US-20120028964-A1 PHARMACEUTICAL COMBINATION SEMINIS VEGETABLE SEEDS, INC. 2012-02-02 US disclosed
US-7902238-B2 2-aminooxazolines as TAAR1 ligands HOFFMANN-LA ROCHE INC. (US) 2011-03-08 US disclosed
EP-2121641-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS F. Hoffmann-Roche AG (CH) 2009-11-25 EP disclosed
US-20090105307-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-23 US disclosed
WO-2008098857-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028964-A1 PHARMACEUTICAL COMBINATION TAAR1, TAAR5, MC2R SPHK1 1278/4885BRD4 967/4885TAAR1 1/4885
US-20130345201-A1 PHARMACEUTICAL COMBINATION TAAR1, TAAR5, MC2R SPHK1 1278/4885BRD4 967/4885TAAR1 1/4885
US-20090105307-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS TAAR1, TAAR5, NPSR1 SPHK1 1861/4885BRD4 2730/4885TAAR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.